MapLight Therapeutics, Inc. MPLT 深 滬
已收盤 05-08 16:00:00 美东时间
27.40
-1.800
-6.16%
華盛通- 最 高29.95
- 今 開29.22
- 成交量 29.22万股
- 最 低 27.00
- 昨 收 29.20
- 總市值 11.68亿
- 52周最高 33.28
- 市盈率 靜 --
- 換手率 0.69%
- 52周最低 12.24
- 委 比 92.10%
- 總股本 4261.01万
- 歷史最高 33.28
- 量 比 1.12
- 振 幅 10.10%
- 歷史最低 12.24
- 每 手 1
- 風險率 4.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
MapLight Therapeutics Completes Enrollment In Its Phase 2 Zephyr Trial Evaluating Ml-007C-MA For The Treatment Of Schizophrenia
The Company also announced completion of the final patient visit in its Phase 2 IRIS trial evaluating ML-004 for the treatment of autism spectrum disorder. The Company expects to report topline results from both Phase 2
05-01 19:06
美股大行评级 | 瑞银上调美光科技目标价从510升至535美元；巴克莱下调Robinhood 目标价从124降至89美元
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5美元升至5.25美元；Benchmark：维持Direct Digital Holdings"投机性买入"评级，目标价从2美元升至8美元
04-09 10:15
MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst
Needham initiates MapLight with Buy, citing ML-007C-MA potential in schizophrenia and AD psychosis, with key readouts expected through 2027.
04-09 02:29
9 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Quince Therapeutics (NASDAQ:QNCX) stock moved upwards by 98.6% to $0.3...
04-08 20:05
TD Cowen Initiates Coverage On MapLight Therapeutics with Buy Rating
TD Cowen analyst Joseph Thome initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating.
04-07 21:52
Earnings Scheduled For March 26, 2026
Companies Reporting Before The Bell • ProShares UltraShort Russell2000 (NYSE:TW...
03-26 19:11
MapLight Therapeutics Q4 EPS $(2.47) Misses $(0.96) Estimate
MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(2.47) per share which missed the analyst consensus estimate of $(0.96) by 156.49 percent. This is a 91.16 percent increase over losses of $(27.95) per
03-26 19:07
美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
Canaccord Genuity Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $35
Canaccord Genuity analyst Sumant Kulkarni initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $35.
03-19 20:55
